Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats
- PMID: 2804976
Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats
Abstract
Nearly all men with metastatic prostatic cancer respond to androgen ablation, demonstrating that at least a portion of their cancer cells are androgen responsive. Unfortunately, however, individual prostatic cancers contain clones of androgen-independent, in addition to androgen-responsive, cancer cells. Due to this tumor cell heterogeneity, essentially all patients treated with androgen ablation alone eventually relapse to a state unresponsive to further antiandrogen therapy; cures are rarely produced. To produce cures, additional nonhormonal therapy targeted at the androgen-independent prostatic cancer cells within the patient should be combined with androgen ablation targeted at the androgen-dependent cancer cells. The validity of such combined chemo-hormonal therapy was tested using, as the experimental model, two members of the Dunning system of serially transplantable rat prostatic cancers. Specifically the slow growing, well differentiated H and the fast growing, poorly differentiated G Dunning sublines were used, since these cover the clinical extremes observed for human prostatic cancers. The chemotherapeutic agent used in combination with surgical androgen ablation (i.e., castration) in these studies was Cytoxan. These studies demonstrate that for both the H and G cancer-bearing rats, the mean survival following combined chemo-hormonal therapy was increased above that found for castrate or Cytoxan when either was used as monotherapy. In addition, an inverse relationship between tumor size at the time of initiation of therapy and the ability of the combined chemo-hormonal therapy to cure animal bearing either the H or G sublines was demonstrated. Such combined chemo-hormonal therapy could only cure a proportion (i.e., 30-40%) of H or G tumor-bearing animals if initiated when the tumor was less than or equal to 0.2 cm3 in size. In contrast, if the tumor was 1-2 cm3 in starting size when the chemo-hormonal therapy was initiated, no animal was cured. Neither of the monotherapies (i.e., castrates or Cytoxan alone) could cure any animals regardless of the starting size.
Similar articles
-
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).Cancer Res. 1999 May 15;59(10):2395-401. Cancer Res. 1999. PMID: 10344749
-
Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer.Cancer Res. 1991 Apr 1;51(7):1760-5. Cancer Res. 1991. PMID: 2004359
-
Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma.Cancer Res. 1981 Dec;41(12 Pt 1):5070-5. Cancer Res. 1981. PMID: 7307008
-
Combined androgen blockade: the gold standard for metastatic prostate cancer.Eur Urol. 1997;32 Suppl 3:70-7. Eur Urol. 1997. PMID: 9267789 Review.
-
Innovative approaches to the hormonal treatment of advanced prostate cancer.Eur Urol. 1997;32 Suppl 3:78-80. Eur Urol. 1997. PMID: 9267790 Review.
Cited by
-
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective.Rev Urol. 2003;5 Suppl 3(Suppl 3):S3-S13. Rev Urol. 2003. PMID: 16985948 Free PMC article.
-
Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective.Rev Urol. 2003;5 Suppl 2(Suppl 2):S3-S13. Rev Urol. 2003. PMID: 16986044 Free PMC article.
-
Ultra-early versus early salvage androgen deprivation therapy for post-prostatectomy biochemical recurrence in pT2-4N0M0 prostate cancer.BMC Urol. 2014 Oct 16;14:81. doi: 10.1186/1471-2490-14-81. BMC Urol. 2014. PMID: 25323845 Free PMC article.
-
Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma.J Neurooncol. 1993 Feb;15(2):97-112. doi: 10.1007/BF01053931. J Neurooncol. 1993. PMID: 8509824
-
Long-term control or possible cure? Treatment of stage D2 prostate cancer under chemotherapy using cisplatin and estramustine phosphate followed by maximal androgen blockade.Int Urol Nephrol. 2008;40(2):365-8. doi: 10.1007/s11255-007-9301-z. Int Urol Nephrol. 2008. PMID: 18092143
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical